Selexipag

Selexipag
Clinical data
Trade names	Uptravi
Other names	ACT-293987, NS-304
License data	US DailyMed: Selexipag;
Routes of; administration	By mouth, intravenous
Drug class	prostacyclin receptor agonist
ATC code	B01AC27 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Bioavailability	49%
Protein binding	99%
Metabolism	Activation by carboxylesterases, inactivation by CYP2C8 and others
Metabolites	ACT-333679, the free acid (active metabolite)
Elimination half-life	0.8–2.5 h (selexipag) and 6.2–13.5 h (ACT-333679)
Excretion	93% faeces
Identifiers
	IUPAC name 2-{4-[(5,6-Diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}-N-(methanesulfonyl)acetamide;
CAS Number	475086-01-2;
PubChem CID	9913767;
IUPHAR/BPS	7552;
DrugBank	DB11362;
ChemSpider	8089417 ;
UNII	5EXC0E384L;
KEGG	D09994 ;
ChEBI	CHEBI:90844 ;
ChEMBL	ChEMBL238804 ;
CompTox Dashboard (EPA)	DTXSID301027959 ;
ECHA InfoCard	100.237.916
Chemical and physical data
Formula	C26H32N4O4S
Molar mass	496.63 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)N(CCCCOCC(=O)NS(=O)(=O)C)C1=CN=C(C(=N1)C2=CC=CC=C2)C3=CC=CC=C3;
	InChI InChI=1S/C26H32N4O4S/c1-20(2)30(16-10-11-17-34-19-24(31)29-35(3,32)33)23-18-27-25(21-12-6-4-7-13-21)26(28-23)22-14-8-5-9-15-22/h4-9,12-15,18,20H,10-11,16-17,19H2,1-3H3,(H,29,31); ; Key:QXWZQTURMXZVHJ-UHFFFAOYSA-N;
	(what is this?) (verify)

Selexipag, sold under the brand name Uptravi, is a medication developed by Actelion for the treatment of pulmonary arterial hypertension (PAH).^[3]^[4] Selexipag and its active metabolite, ACT-333679 (or MRE-269, the free carboxylic acid), are agonists of the prostacyclin receptor, which leads to vasodilation in the pulmonary circulation.^[5] It is taken by mouth or administered intravenously.^[3]^[6]

The most common side effects include headache, diarrhea, nausea and vomiting, jaw pain, myalgia (muscle pain), pain in the limbs, arthralgia (joint pain) and flushing.^[4]

It is available as a generic medication.^[7]

^ "Prescription medicines: registration of new chemical entities in Australia, 2016". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 10 April 2023. Retrieved 10 April 2023.
^ "Health Canada New Drug Authorizations: 2016 Highlights". Health Canada. 14 March 2017. Retrieved 7 April 2024.
^ ^a ^b ^c "Uptravi- selexipag tablet, coated Uptravi Titration Pack- selexipag kit". DailyMed. Archived from the original on 30 July 2021. Retrieved 30 July 2021.
^ ^a ^b ^c "Uptravi EPAR". European Medicines Agency. 1 July 2022. Archived from the original on 12 May 2021. Retrieved 27 August 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^ Sitbon O, Morrell N (December 2012). "Pathways in pulmonary arterial hypertension: the future is here". European Respiratory Review. 21 (126): 321–327. doi:10.1183/09059180.00004812. PMC 9487224. PMID 23204120.
^ "Uptravi (selexipag) Receives FDA Approval for Intravenous Use in Adult Patients with Pulmonary Arterial Hypertension (PAH)". Janssen Pharmaceutical Companies (Press release). 30 July 2021. Retrieved 30 July 2021.
^ "Competitive Generic Therapy Approvals". U.S. Food and Drug Administration (FDA). 29 June 2023. Archived from the original on 29 June 2023. Retrieved 29 June 2023.

[1] "Prescription medicines: registration of new chemical entities in Australia, 2016". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 10 April 2023. Retrieved 10 April 2023.

[2] "Health Canada New Drug Authorizations: 2016 Highlights". Health Canada. 14 March 2017. Retrieved 7 April 2024.

[Uptravi_FDA_label-3] "Uptravi- selexipag tablet, coated Uptravi Titration Pack- selexipag kit". DailyMed. Archived from the original on 30 July 2021. Retrieved 30 July 2021.

[Uptravi_EPAR-4] "Uptravi EPAR". European Medicines Agency. 1 July 2022. Archived from the original on 12 May 2021. Retrieved 27 August 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[5] Sitbon O, Morrell N (December 2012). "Pathways in pulmonary arterial hypertension: the future is here". European Respiratory Review. 21 (126): 321–327. doi:10.1183/09059180.00004812. PMC 9487224. PMID 23204120.

[6] "Uptravi (selexipag) Receives FDA Approval for Intravenous Use in Adult Patients with Pulmonary Arterial Hypertension (PAH)". Janssen Pharmaceutical Companies (Press release). 30 July 2021. Retrieved 30 July 2021.

[7] "Competitive Generic Therapy Approvals". U.S. Food and Drug Administration (FDA). 29 June 2023. Archived from the original on 29 June 2023. Retrieved 29 June 2023.

[1]

[2]

[3]

[4]

[5]

[6]

[7]